| Revenue growth | Full-year revenue up 2%; Q4 up 2% due to supply constraints. |
|---|---|
| Margins | EBITDA margins improved 290bps to 34% through efficiency and mix shift. |
| Demand visibility | Strong demand in vaccines (Shingrix) and respiratory; mixed for general medicine. |
| Management confidence | Balanced and optimistic regarding the pivot toward specialty and oncology segments. |
Growth
Full-year EBITDA grew 11% and PAT 10% through margin expansion. Specialty/Innovation portfolio now contributes 6% of revenue, up from 2%.
Outlook
Targeting double-digit top-line growth. Management aims for a 10% revenue contribution from the innovative 'freshness index' portfolio.
Risks
Persistent supply constraints at a key CMO impacted revenue growth by 3.5%. Muted growth in the core general medicine portfolio remains a structural drag.
Earnings Call filed with BSE, NSE: GLAXO. Summary written with AI assistance from the document.
GlaxoSmithKline Pharmaceuticals Ltd: key numbers
- Share price
- ₹2,755.00
- Market cap
- ₹46,671 Cr
- Revenue (annual)
- ₹3,822 Cr
- Net profit (annual)
- ₹1,036 Cr
- P/E (TTM)
- 43.7×Sector 47.4×
- Promoter holding
- 75.00%+0.00% QoQ
- FII holding
- 4.79%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from GlaxoSmithKline Pharmaceuticals Ltd
All →GlaxoSmithKline Pharmaceuticals Annual General Meeting
GSK Pharma's postal ballot approved Ms. Natland as NED and Mr. Akshikar's MD re-appointment. Both resolutions cleared with over 99% shareholder support.
GlaxoSmithKline Pharmaceuticals Annual General Meeting
GlaxoSmithKline Pharmaceuticals issued a corrigendum for its August 3, 2026, postal ballot notice, correcting a typographical error in a reported salary figure.
GlaxoSmithKline Pharmaceuticals Price Movement Clarification
GlaxoSmithKline Pharmaceuticals clarified that recent trading volume increases are purely market-driven. The company confirmed all material disclosures have been made according to SEBI regulations.
GlaxoSmithKline Pharmaceuticals Business Update
GlaxoSmithKline Pharmaceuticals received an income tax refund intimation of Rs 4.99 Crore for the assessment year 2025-2026.
- Value
- ₹4.99 Cr
GlaxoSmithKline Pharmaceuticals Annual General Meeting
GlaxoSmithKline Pharmaceuticals has issued a Postal Ballot notice for shareholder approval. The resolutions involve appointing Karine J F Natland and re-appointing Bhushan Akshikar as Managing Director.
GlaxoSmithKline Pharmaceuticals Legal & Regulatory
GlaxoSmithKline Pharmaceuticals received a ₹52.00 Crore tax refund plus ₹42.09 Crore interest income following a favorable CIT-Appeal order for assessment year 1984-85.
- Value
- ₹94.09 Cr